Good first six months in 2009 for Boehringer Ingelheim

Boehringer IngelheimThe pharmaceutical company Boehringer Ingelheim again posted gratifying growth in local currency (+8.3 percent) over the previous year in the first six months of 2009. Consolidated in euro, this reflected growth of + 15.7 percent thanks to the positive exchange rates, with net sales of EUR 6,388 million compared with EUR 5,522 million in the first six months of the previous year.

The operating income developed equally well over the previous year. Currency effects played their part here, too, adding to the positive development of the individual businesses.

In the first six months, net sales of Boehringer Ingelheim again outpaced the growth on the world pharma market.

Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors: "We have posted growth in our business areas Human Pharmaceuticals, thanks in particular to the success of our innovative prescription medicines, and in Animal Health, thanks to the growth in the segment of vaccines. Despite the negative impact in some areas as a result of the financial crisis, local business development in the first half of 2009 shows that Boehringer Ingelheim is maintaining its growth course, virtually unchanged, and continues to outpace the pharmaceutical market," said Andreas Barner.

Boehringer Ingelheim is again expecting sales growth in local currency in the year as a whole to outpace the world pharma market; for the tenth time in succession. Growth in euro depends greatly on the exchange rate trends of the US dollar and the Japanese yen.

Due to important patent expiries, for instance for the drug Flomax® in the USA, Boehringer Ingelheim in 2010 is likely to see virtually no significant growth after ten years. Yet already in 2011 a new period of growth will be heralded from new innovative medications, which already will be introduced in 2010. These launches will trigger additional investments in 2010.

In the first six months of 2009, net sales in our core Prescription Medicines business rose to EUR 5,107 million, signifying growth of +9.1 percent in local currency (+17.3 percent in euro).

International key brands accounted for 79 percent of net sales in the Prescription Medicines business with local growth of +13.3 percent over the previous year. With sales of EUR 1,176 million, Spiriva®, for the treatment of chronic obstructive pulmonary disease (COPD), secured further strong growth of +15.0 percent in the first half of 2009 compared with the previous year. The leading cardiovascular product Micardis®, for the treatment of high blood pressure, achieved a marked increase in sales of +7.6 percent over the previous year to total EUR 709 million. In the field of urological disorders, the company markets Flomax®/Alna® for the treatment of benign prostatic hyperplasia. This product achieved growth of +27.2 percent over the previous year with net sales of EUR 709 million.

In the first six months of 2009, the Consumer Health Care business (CHC) posted net sales in the amount of EUR 609 million and local growth of +1.0 percent (+7.1 percent in euro) over the previous year. The operating income in this segment suffered considerably in the last six months in the wake of the financial crisis.

The international CHC key brands, including Dulcolax®, Mucosolvan® and Buscopan®, nevertheless posted growth of +6.9 percent in local currency.

Business with Industrial Customer secured sales of EUR 382 million in the first six months of 2009, more or less on a par with the previous year (local decline of -2.3 percent, +0.3 percent growth in euro).

The Animal Health business achieved strong growth of +27.9 percent in local currency (+32.5 percent in euro), with sales of EUR 286 million. The most significant growth driver was again the innovative pig vaccine Ingelvac Circoflex®.

The results from the company's own research and development are also extremely encouraging and offer a solid basis for the future growth of Boehringer Ingelheim:

While Pradaxa® (dabigatran etexilate) for the "primary prevention of venous thrombotic events following elective hip or knee replacement surgery" has developed very well in Europe and some other non-European countries, the company now awaits the results of RE-LY® and RE-COVER®. These two large-scale studies in the new indications "stroke prevention associated with atrial fibrillation" and "treatment of acute venous thrombosis" are currently being evaluated; the results are to be published end of August and in November, 2009.

The results of RE-LY®, the largest study worldwide in stroke prevention associated with atrial fibrillation, are of particular importance as they herald the start of a new era in anticoagulant therapy after more than 50 years with no major progress. A medical breakthrough in stroke prevention associated with atrial fibrillation would be a convincing alternative to the complicated therapy with vitamin K antagonists currently available.

The substance flibanserin is currently investigated as a potential pharmaceutical treatment for pre-menopausal women suffering from Hypoactive Sexual Desire Disorder (HSDD).

The late stage clinical trial programme BOUQUET® for the investigation of efficacy and safety of flibanserin, includes 5,000 HSDD sufferers at over 300 clinical study sites across North America and Europe. Results of the pivotal phase III studies are expected to be released in late 2009.

In oncology, the phase III studies with BIBW 2992 (designated tradename Tovok®), a tumour growth factor inhibitor, and the innovative triple angiokinase inhibitor BIBF 1120 (designated tradename Vargatef®) in the indication "non-small-cell lung cancer" are on track. BIBF 1120 (Vargatef®) is also being tested as first-line therapy for ovarian cancer. A phase III study with 1,200 patients is being prepared in addition to the scheduled studies in prostate and intestinal cancer.

The phase III clinical study with the oral diabetes drug linagliptine is nearing completion. More than 4,000 patients were enrolled for the study and the first pivotal study has been unblinded for analysis. Following positive results from short-term phase IIb studies with another substance, an SGLT-2-inhibitor for the treatment of type-2 diabetes, recruitment for the 12-week studies with mono- and combination therapy is already well advanced.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...